Month: January 2026

Kvika banki hf.’s („Kvika“or „the Company“) Nomination Committee (“the Committee”) invites those interested to submit their nominations or candidacies to the Board of Directors of the Company to the Committee. The Committee prepares and presents proposals for candidates for election to the Company’s Board of Directors at its Annual General Meeting (AGM) and at shareholder meetings where board elections are on the agenda. The Committee’s proposals shall aim to ensure that the Board of Directors is composed at any given time of diverse range of knowledge and experience that is useful to the Company in policymaking and monitoring in the environment in which the company operates at any given time. The Nomination Committee has an advisory role in the selection of directors of Kvika and shall submit its proposals to a shareholders’...

LAS VEGAS, Jan. 09, 2026 (GLOBE NEWSWIRE) — AMC Robotics Corporation (Nasdaq: AMCI) (“AMC Robotics” or the “Company”), a leading AI-driven robotics solutions company, today announced its participation at CES® 2026. The Company demonstrated its latest artificial intelligence–powered technologies, headlined by Kyro™, its proprietary quadruped robotic platform. The demonstration comes at a pivotal time for the industry. During his CES 2026 keynote, NVIDIA CEO Jensen Huang declared that “the ChatGPT moment for physical AI is here,” describing a new era where machines move beyond digital processing to “understand, reason, and act in the real world.” At CES, AMC Robotics showcased how Kyro™ utilizes these breakthroughs through advanced mobility, autonomous navigation, and AI-enabled perception. By integrating these “thinking”...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending positive results, an NDA submission is planned for the second half of 2026 Accelerating U.S. launch readiness for QTORIN™ rapamycin for microcystic LMs which has the potential to become the first FDA-approved therapy and a first-line, standard-of-care treatment for this serious, lifelong disease affecting an estimated more than 30,000 diagnosed patients in the U.S. Following positive Phase 2 results for QTORIN™ rapamycin for the treatment of cutaneous venous malformations announced in December 2025, requested a Preliminary Breakthrough Therapy Designation Advice meeting with the U.S. Food and...

Seasoned Capital Markets and Financial Executive to Drive Strategic Growth and Market Expansion BELVIDERE, NJ, Jan. 09, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced that Matthew McConnell, a member of the Company’s Board of Directors, has joined Edible Garden’s senior leadership team full time as Executive Vice President Strategic Partnerships, effective immediately. In this role, Mr. McConnell will be responsible for advancing the Company’s strategic initiatives, strengthening relationships with investors and partners, and supporting long-term growth objectives across key channels. Mathew has worked on Wall Street for over 40...

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) — Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase agreements with several investors. Ping An Biomedical Co., Ltd. has entered into a series of share purchase agreements from several investors: Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor. This round of investment further strengthens the company’s long-term development in biopharmaceutical R&D, medical technology, and innovation. Yao Jinbo of 58 Group: An Entrepreneur with a Proven Track Record of Capturing Megatrends As one...

Celebration, FL, Jan. 09, 2026 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech enterprise, today announced an initial closing of an $11,000,000 note under its previously announced $250 million private placement convertible note facility (the “Note Facility”). The Company’s total available financing capacity, including the initial closing, is $1.25 billion when combined with its existing $1 billion equity purchase facility. La Rosa will deploy this capital to establish a strategic reserve, providing the liquidity and financial agility to scale its AI infrastructure strategy and develop a premium real estate portfolio of advanced data center facilities optimized for AI workloads.  Since the initial announcement of these facilities, the Company has been evaluating several...

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease. “We look forward to a constructive discussion with the FDA as we work toward a timely resolution regarding an accelerated approval pathway for AMT-130,” said Matt Kapusta, chief executive officer at uniQure. “The Huntington’s disease community, including patients and clinicians, has emphasized the profound unmet medical need and the importance...